Topical application of GSK2981278 (1% in ointment; for three days) results in a reduction of skin redness and scaling, along with a 23% reduction in epidermal thickness, indicating its effectiveness in attenuating inflammation in a mouse model of psoriasis^[1].

GSK2981278 significantly suppresses IL-17A and IL-22 protein secretion in a concentration-dependent manner with an IC50 of 3.2 nM, especially noticeable during 5 days of culture under Th17 skewing conditions^[1].

At varying concentrations (0.3, 1, 3, 10, 30, 100, 300, 1000 pM; over 5 days), GSK2981278 shows potent and selective inhibition of IL-17 and IL-22 levels, with concentrations ≥3 nM leading to nearly complete inhibition of IL-17A protein secretion^[1].